Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project

Autor: Mike Whelan, Kenneth C. McCullough, Odile Leroy, Guus F. Rimmelzwaan, Anke Huckriede, Eva van Doorn, Eduard Daniel Leendert Schmidt, Heng Liu, Henderik W. Frijlink, Eelko Hak
Přispěvatelé: Virology
Jazyk: angličtina
Rok vydání: 2016
Předmět:
0301 basic medicine
Economic growth
Biomedical Research
Seasonal influenza
DOUBLE-BLIND
0302 clinical medicine
Pandemic
IMMUNE-RESPONSE
Live attenuated influenza vaccine
Medicine
European commission
030212 general & internal medicine
CHITOSAN
MUCOSAL ADJUVANT
media_common
Vaccines
630 Agriculture
Broadly protective
Infectious Diseases
Influenza Vaccines
EU consortia
Molecular Medicine
ANTIBODY-RESPONSES
H5N1 vaccine
Influenza vaccine
C-DI-GMP
CLINICAL-TRIAL
03 medical and health sciences
SDG 3 - Good Health and Well-being
Research Support as Topic
Correlates of protection
Influenza
Human
Humans
media_common.cataloged_instance
European Union
HEMAGGLUTININ-STEM
European union
Pandemics
H5N1 VACCINE
General Veterinary
General Immunology and Microbiology
business.industry
Public Health
Environmental and Occupational Health
Outbreak
ANKARA MVA
Influenza
Biotechnology
030104 developmental biology
570 Life sciences
biology
business
Zdroj: Vaccine, 34(48), 5845-5854. Elsevier
ISSN: 0264-410X
DOI: 10.7892/boris.96156
Popis: Due to influenza viruses continuously displaying antigenic variation, current seasonal influenza vaccines must be updated annually to include the latest predicted strains. Despite all the efforts put into vaccine strain selection, vaccine production, testing, and administration, the protective efficacy of seasonal influenza vaccines is greatly reduced when predicted vaccine strains antigenically mismatch with the actual circulating strains. Moreover, preparing for a pandemic outbreak is a challenge, because it is unpredictable which strain will cause the next pandemic. The European Commission has funded five consortia on influenza vaccine development under the Seventh Framework Programme for Research and Technological Development (FP7) in 2013. The call of the EU aimed at developing broadly protective influenza vaccines. Here we review the scientific strategies used by the different consortia with respect to antigen selection, vaccine delivery system, and formulation. The issues related to the development of novel influenza vaccines are discussed. (C) 2016 Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: